Description
Lead compound administered as an oral drug
Anti-PD-1/PD-L1 immunotherapy has become a major strategy in the fight against cancer with the aim of reprogramming or activating anti-tumor immunity to kill tumor cells without damaging normal cells.
WAVEIMMUNE compounds are small molecules, PD-L1 inhibitors with solid in vitro and in vivo results:
•AliPD1 is the lead of the series
•In vitro target engagement
•In vivo significant reduction in tumor volume in a colorectal carcinoma